Compumedics Limited (AU:CMP)
ASX:CMP
CMP Stock Chart & Stats
AU$0.34
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.34
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.24 - AU$0.45
Previous CloseN/A
Volume3.00K
Average Volume (3M)87.45K
Market Cap
AU$55.93M
Enterprise ValueAU$67.96M
Total Cash (Recent Filing)AU$2.00M
Total Debt (Recent Filing)AU$14.03M
Price to Earnings (P/E)62.7
Beta0.65
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding199,761,750
10 Day Avg. Volume153,799
30 Day Avg. Volume87,448
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)2.12
Price to Sales (P/S)0.91
P/FCF Ratio99.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained revenue growth (24.45%) signals expanding market penetration of Compumedics’ diagnostic systems. A growing top line supports a larger installed base, which should drive recurring software, consumable and service revenues and provide resilience over the medium term.
High Gross MarginA gross margin around 60.71% indicates the business captures material value per sale, supporting structural profitability if operating costs are controlled. High product and software margins create room for R&D and service investment, strengthening long-term competitive positioning.
Manageable LeverageDebt-to-equity of 0.64 reflects moderate leverage that affords financial flexibility to support inventory, channel development and product rollout without excessive solvency strain. Manageable leverage lowers refinancing risk and supports strategic investment over months ahead.
Bears Say
Weak ProfitabilityNegative net margin and near‑break‑even EBIT show the core operations are not yet delivering sustainable profitability. Continued weak operating returns limit retained earnings, constrain reinvestment capacity and raise the need for either sustained margin recovery or external funding.
Poor Cash ConversionSeverely negative free cash flow growth and an operating cash flow to net income ratio near zero indicate weak cash generation. Poor cash conversion undermines the company’s ability to fund working capital, service debt or invest organically without raising external capital in the medium term.
Negative Return On EquityA negative ROE (-5.83%) signals the company is currently destroying shareholder value. Persistently negative returns erode equity buffers, constrain self‑funding for R&D and channel expansion, and increase dependence on non‑operational measures to restore shareholder returns.
Compumedics Limited News
CMP FAQ
What was Compumedics Limited’s price range in the past 12 months?
Compumedics Limited lowest share price was AU$0.24 and its highest was AU$0.45 in the past 12 months.
What is Compumedics Limited’s market cap?
Compumedics Limited’s market cap is AU$55.93M.
When is Compumedics Limited’s upcoming earnings report date?
Compumedics Limited’s upcoming earnings report date is Sep 01, 2026 which is in 154 days.
How were Compumedics Limited’s earnings last quarter?
Compumedics Limited released its earnings results on Feb 24, 2026. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.001.
Is Compumedics Limited overvalued?
According to Wall Street analysts Compumedics Limited’s price is currently Overvalued.
Does Compumedics Limited pay dividends?
Compumedics Limited does not currently pay dividends.
What is Compumedics Limited’s EPS estimate?
Compumedics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Compumedics Limited have?
Compumedics Limited has 199,761,750 shares outstanding.
What happened to Compumedics Limited’s price movement after its last earnings report?
Compumedics Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.353%.
Which hedge fund is a major shareholder of Compumedics Limited?
Currently, no hedge funds are holding shares in AU:CMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compumedics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.56%
12-Months-Change
Fundamentals
Return on Equity
0.48%
Trailing 12-Months
Asset Growth
13.30%
Trailing 12-Months
Company Description
Compumedics Limited
Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Okti; Grael PSG; Grael DC; Somfit/Somfit Pro, a wearable device; TCM5 FLEX Transcutaneous monitor; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; Profusion neXus 360, a web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and HD Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, summit IP, and persyst software products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was incorporated in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited operates as a subsidiary of D & DJ Burton Holdings Pty Ltd.
Technical Analysis
Impedimed Limited
―
Somnomed Limited
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―